ArticleDiscover oncology2026
Collagen type I alpha 2 acts as a potential diagnostic biomarker and therapeutic targets for the prognosis in gastric cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundGastric cancer (GC) is a common digestive tract cancer whose high heterogeneity and invasiveness lead to a low survival rate. Therefore, it is necessary to explore the potential molecular mechanism of GC.
methodsThree genes and one miRNA expression microarray dataset were downloaded from the GEO database. The gene expression profiles of the cancer group and normal group were compared in each dataset, and differentially expressed genes (DEGs) and miRNAs were identified with GEO2R. GO enrichment and KEGG pathway analysis of DEGs were performed with the R package clusterProfiler. The interaction network of DEGs was visualized with Cytoscape, and clusters and key genes were identified. According to the key DEGs, a prognostic risk model of GC was established by Cox regression. The patients were subdivided into high-risk and low-risk groups based on the median value of the risk score, and the model performance was evaluated by ROC curve and survival analyses. The risk model was combined with clinicopathological features to establish a nomogram, and a calibration chart was used to evaluate the prediction accuracy of the nomogram. The ROC curve was drawn to predict the ability of genes to differentiate tumour tissues from normal tissues. The starBase database was used to construct a regulatory network consistent with the miRNA-mRNA hypothesis. The expression of COL1A2 was analysed by immunohistochemistry/immunocytochemistry (IHC/ICC) in 150 patients with gastric cancer and a GC cell line. The correlations between COL1A2 expression and clinical features were analysed.
resultsA total of 106 DEGs and 113 differentially expressed miRNAs were identified from the gastric cancer dataset. PPI network screening revealed the two most significant modules and identified the dominant gene. A prognostic risk model composed of six prognostic genes (COL1A2, COL1A1, COL3A1, SPARC, LUM and BGN) was constructed by Cox regression analysis. The prognosis of the high-risk group was poor (P < 0.001). ROC curve analysis (AUC = 0.732) showed that the model better predicted the 5-year survival rate of patients. In addition, the six prognostic genes had appropriate diagnostic ability for GC. A potential ceRNA network of model genes in GC was constructed through the starBase database. IHC showed that COL1A2 was highly expressed in gastric cancer and GC cells. COL1A2 expression was significantly correlated with lymph node metastasis.
conclusionThis study reveals the potential biomarkers and related pathways of GC and provides a theoretical basis for the diagnosis and prognosis prediction of GC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.